Table 3 Univariate prognostic factor... | American Society of Hematology

Table 3

Univariate prognostic factor analyses for allografted patients (log-rank)

End point/variable	Univariate analysis (Log-rank)
End point/variable	P	HR	Lower CL	Upper CL
Overall survival
17p− vs other karyotypes	.60	1.33	0.45	3.91
Refractory at SCT	< .001*	3.4*	1.4*	8.26*
TCD vs FC	.004	4.84*	1.64*	14.3*
FBC vs FC	.51	1.51	0.44	5.17
Age ≥ 55 vs < 55 years	.67	1.16	0.58	2.33
Purine analogue refractory	.091	1.82	0.91	3.63
WMUD vs sibling donor	.81	1.11	0.47	2.66
PMUD vs sibling donor	.49	1.58	0.43	5.84
Previous autoSCT	.54	0.8	0.39	1.64
Previous regimens > 3 vs ≤ 3	.085	1.85	0.92	3.7
Years from diagnosis to SCT ≥ 5 vs <5	.14	0.59	0.3	1.19
Alemtuzumab for remission induction	.83	1.09	0.48	2.49
ECOG 0 vs 1	.78	0.92	0.50	1.69
HCT-CI 0 vs > 0	.99	0.99	0.50	1.97
BM infiltration at SCT > 50% vs ≤50%*	.058	2.16	0.98	4.78
Event-free survival
17p− vs other karyotypes	.98	1.01	0.44	2.31
Refractory at SCT	.002	3.12*	1.46*	6.65*
TCD vs FC	<.001*	4.2*	1.67*	10.5*
FBC vs FC	.35	0.66	0.27	1.58
Age	.53	0.84	0.48	1.46
Purine analogue refractory	.82	1.07	0.61	1.95
WMUD vs sibling donor	.88	0.93	0.38	2.31
PMUD vs sibling donor	.49	0.79	0.40	1.54
Previous autoSCT	.37	0.77	0.43	1.38
Previous regimens > 3 vs ≤ 3	.36	1.31	0.73	2.33
Years from diagnosis to SCT ≥ 5 vs < 5	.33	0.76	0.44	1.33
Alemtuzumab for remission induction	.60	0.84	0.44	1.61
ECOG 0 vs 1	.8	0.91	0.43	1.91
HCT-CI 0 vs >0	.73	0.86	0.37	1.99
BM infiltration at SCT > 50% vs ≤ 50%*	.86	1.09	0.40	2.93

End point/variable	Univariate analysis (Log-rank)
End point/variable	P	HR	Lower CL	Upper CL
Overall survival
17p− vs other karyotypes	.60	1.33	0.45	3.91
Refractory at SCT	< .001*	3.4*	1.4*	8.26*
TCD vs FC	.004	4.84*	1.64*	14.3*
FBC vs FC	.51	1.51	0.44	5.17
Age ≥ 55 vs < 55 years	.67	1.16	0.58	2.33
Purine analogue refractory	.091	1.82	0.91	3.63
WMUD vs sibling donor	.81	1.11	0.47	2.66
PMUD vs sibling donor	.49	1.58	0.43	5.84
Previous autoSCT	.54	0.8	0.39	1.64
Previous regimens > 3 vs ≤ 3	.085	1.85	0.92	3.7
Years from diagnosis to SCT ≥ 5 vs <5	.14	0.59	0.3	1.19
Alemtuzumab for remission induction	.83	1.09	0.48	2.49
ECOG 0 vs 1	.78	0.92	0.50	1.69
HCT-CI 0 vs > 0	.99	0.99	0.50	1.97
BM infiltration at SCT > 50% vs ≤50%*	.058	2.16	0.98	4.78
Event-free survival
17p− vs other karyotypes	.98	1.01	0.44	2.31
Refractory at SCT	.002	3.12*	1.46*	6.65*
TCD vs FC	<.001*	4.2*	1.67*	10.5*
FBC vs FC	.35	0.66	0.27	1.58
Age	.53	0.84	0.48	1.46
Purine analogue refractory	.82	1.07	0.61	1.95
WMUD vs sibling donor	.88	0.93	0.38	2.31
PMUD vs sibling donor	.49	0.79	0.40	1.54
Previous autoSCT	.37	0.77	0.43	1.38
Previous regimens > 3 vs ≤ 3	.36	1.31	0.73	2.33
Years from diagnosis to SCT ≥ 5 vs < 5	.33	0.76	0.44	1.33
Alemtuzumab for remission induction	.60	0.84	0.44	1.61
ECOG 0 vs 1	.8	0.91	0.43	1.91
HCT-CI 0 vs >0	.73	0.86	0.37	1.99
BM infiltration at SCT > 50% vs ≤ 50%*	.86	1.09	0.40	2.93

autoSCT indicates autologous stem cell transplantation; BM, bone marrow; CL, confidence limit; ECOG, Eastern Cooperative Oncology Group; FBC, FC + busulfan; FC, fludarabine-cyclophosphamide; HCT-CI, hematopoietic cell transplantation comorbidity index; HR, hazard ratio; PMUD, partially matched unrelated donor; SCT, stem cell transplantation; SIB, 10 of 10 allele-matched sibling; TCD, FC + total body irradiation 2Gy + in vivo alemtuzumab; WMUD, well-matched unrelated donor.

Significant.

†A total of 60 patients with data available.

View Large

This Feature Is Available To Subscribers Only